Fungal Protein Market

How big is Fungal Protein Market in 2026?

USD 515.0 million in 2026 and USD 1387.6 million by 2036 at a 10.4% CAGR.

Demand for fungal protein is projected to advance at 10.4% CAGR from 2026 to 2036 as food manufacturers widen protein sourcing beyond conventional animal and plant inputs. Enifer released its first commercial PEKILO mycoprotein batch for pet-food development in March 2026 to support customer formulation trials. The first commercial batch gave customers enough material for structured application trials instead of pilot-only testing. Repeat orders depend on delivered cost and stable performance within the finished formulation once technical qualification is completed.

Novel-food status attaches to each defined ingredient and production route, so commercial timing differs sharply by jurisdiction. Switzerland updated its novel-food guidance in 2026 and requires a technical safety dossier for fungi-derived foods that qualify as novel. The United States uses GRAS pathways for qualifying ingredients and Great Britain uses regulated-product risk assessment. These routes alter launch sequencing because regulatory evidence must match the organism and manufacturing process ahead of regular purchase commitments.

Key Takeaways of Fungal Protein Market

• Demand is expanding as food and nutrition formulators test fungal protein ingredients for protein density, fibrous texture, neutral flavor, and supply diversification in routine applications.
• Based on source, yeast is projected to account for 37.8% in 2026 due to mature fermentation routes and broad ingredient familiarity.
• By end use application, food & beverage is forecast to represent 37.4% in 2026 driven by use in beverages, bakery, prepared foods, and meat alternatives.
• The USA is forecast to record 12.7% CAGR through 2036, giving technical-sales teams the fastest profiled country growth rate in the authorised dataset.
• Product-specific safety review and sensory qualification can delay repeat orders until each formulation satisfies local rules and the finished-product specification.
• Some of the key players in this market include Angel Yeast Co., Ltd., The Protein Brewery, Enifer, Revyve, MycoTechnology, Inc., Lallemand Bio-Ingredients, Onego Bio, and The EVERY Company.

Analyst Perspective

"Fungal protein economics depend on fermentation yield and performance inside the customer's formulation, so biomass volume alone does not secure repeat orders. Companies that control organism-specific safety evidence and solve flavor or texture problems have the clearest route from trial volume to contracted supply."

- Nandini Roy Choudhury, Principal Consultant, Future Market Insights

How is the Fungal Protein Market segmented?

The fungal protein market is segmented by source and end use application, with region used for geographic analysis.

Source covers yeast, baker's yeast, Fusarium venenatum, brewer's yeast, and mushroom-derived protein. End use application covers food & beverage, processed food, animal nutrition, dairy, pet food, bakery, pharmaceuticals, and aquaculture. Regional analysis covers North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East and Africa.

What makes Yeast central to the Source category?

Commercial yeast infrastructure gives protein producers well-understood organism handling and downstream processing routes from fermentation to standardized powder at scale. Brewer's yeast protein enters formulations where manufacturers already compare alternative protein sources during flavor and nutrition qualification.

• By source, yeast is estimated to hold 37.8% in 2026 owing to mature fermentation routes and broad familiarity among food and nutrition formulators.
• The FDA closed GRN 1248 with no questions in September 2025 for Kluyveromyces marxianus yeast biomass. That decision gives manufacturers a current USA example of defined yeast biomass completing GRAS review ahead of commercial food use.

Why does Food & Beverage lead the End use Application category?

Food manufacturers can test fungal protein in beverages and prepared foods without tying the ingredient to one meat-alternative format. Precision fermentation ingredients compete for fortification budgets in products, whereas fibrous mycoprotein contributes structure to finished foods that require texture.

• Food & beverage is set to lead the end use application category with 37.4% share in 2026 due to qualification routes in beverages and prepared foods.
• In January 2026, the Food Standards Agency and Food Standards Scotland published RP1437 for pea and rice protein fermented by shiitake mycelia. Its intended uses cover beverages, baked goods, dairy analogues, meat alternatives, and other foods that require product-specific qualification.

What are the drivers, restraints and opportunities in the Fungal Protein Market?

Broader protein formulation needs increase trial activity, regulatory and sensory qualification limit conversion, and application-specific fermentation programs offer the clearest revenue route.

• Driver: Food manufacturers need additional protein sources that solve defined formulation problems without forcing a full redesign of existing processing lines.
• Restraint: Organism-specific safety review and finished-product testing can extend qualification timelines ahead of recurring commercial orders.
• Opportunity: Producers can target food and feed categories that use fungal protein for texture, protein density, digestibility, or shelf-stable ingredient functionality.

Food companies are widening technical trials as fermented protein gains a larger role beside incumbent animal and plant ingredients. The Protein Brewery closed a Series B round in September 2025 to expand Fermotein production and application work. The round funds larger production and customer testing needed for structured comparisons with incumbent proteins. Revenue follows once Fermotein performs within the customer's own cost and processing limits.

Regulatory review is a material restraint because approvals do not transfer automatically between organisms or products. In March 2026, the FDA ceased evaluating GRN 1268 for Rhizomucor pusillus mycelial biomass at the notifier's request. A withdrawn notice does not establish a safety failure and should not be presented as one. The filing status means developers must allow for dossier changes or withdrawals within qualification schedules.

Animal nutrition gives fungal protein a separate commercialization route since formulators already compare proteins by digestibility and delivered nutrient value. Enifer and FS announced a June 2025 project designed for 500 tonnes of PEKILO Pet and PEKILO Aqua output each year from corn-ethanol side streams. Animal feed alternative protein programs can use fermentation beside conventional feed ingredients during digestibility and feeding trials. The same economics apply to microbial protein once feed performance and supply reliability are documented.

Which country CAGRs are profiled in the Fungal Protein Market?

Country	CAGR
USA	12.7%
Japan	12.3%
UK	11.1%
Germany	10.3%
South Korea	8.9%

How do country-level CAGRs compare in the Fungal Protein Market?

The five forecasts span 3.8 percentage points from the USA at 12.7% to South Korea at 8.9%. The USA and Japan form the upper pair above 12%, with the UK in the middle at 11.1%. Germany follows at 10.3%. South Korea records the lowest profiled rate within this five-country set.

• USA formulators working on functional food ingredients can test fungal proteins in beverages and prepared foods during customer trials.
• Japan's convenience and nutrition channels offer compact high-protein formats that reduce dependence on meat-alternative positioning.
• UK foodservice manufacturers can test fungal proteins in familiar savory formats ahead of broader packaged-food launches.
• German sports-nutrition and bakery manufacturers provide protein-fortification routes that do not depend on meat-alternative demand.
• South Korea's concentrated branded-food groups make a few customer wins disproportionately important for early commercial scale.

The full report provides country-level CAGR analysis across North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East and Africa.

Country-wise Analysis

• Regulatory status determines how quickly USA food developers take a new fungal protein from samples into customer trials. The USA is estimated to post 12.7% CAGR over the forecast period, tied to active protein reformulation and a large technical customer base. In November 2025, the FDA closed GRN 1255 with no questions for Fusarium compactum fungal protein intended for multiple food categories. That decision gives USA formulators a current route for defined fungal biomass with broad intended uses. Taste and processing stability require application trials ahead of national launch. Local technical teams can convert regulator-reviewed ingredients into contracted volume faster than overseas developers working through distributors.
• In Japan, food companies already use microbial processes in familiar domestic foods and fermentation has a practical operating base. In June 2026, the Ministry of Agriculture Forestry and Fisheries stated that food tech is one of 17 strategic fields under the national growth agenda. Japan's fungal protein outlook is anticipated to advance at 12.3% CAGR over the assessment period, because public food-tech planning directs investment toward new production technologies. Local sensory expectations and conservative launch testing slow conversion despite technical acceptance of the fermentation route. Japanese formulation partners shorten application work by returning local sensory feedback ahead of national launch decisions for major brands.
• Long retail exposure to mycoprotein gives British manufacturers a familiar category for evaluating newer fungal proteins in formulation trials. Category familiarity cannot transfer safety status from a proven mycoprotein to another organism or manufacturing route. In August 2025, Quorn removed artificial ingredients from its core frozen Mince and Pieces and rolled the refreshed range into major UK supermarkets. Fungal protein demand in the UK is forecast to rise at 11.1% CAGR over the forecast period, supported by category recognition. New ingredients must prove taste and processing performance inside each formulation. Category familiarity lowers education effort but does not remove ingredient-specific review.
• German ingredient teams test alternative proteins against demanding food-processing specifications, and technical acceptance does not remove safety scrutiny for unfamiliar sources. The German fungal protein sector is projected to record 10.3% CAGR during the assessment period, given its food-manufacturing base and access to the EU single market. Destatis recorded 5,484 food and feed manufacturing establishments with 599,788 employees in 2025. That industrial depth gives fungal-protein developers many potential qualification sites without proving automatic adoption. Regulatory caution keeps organism documentation and contaminant control central to customer trials. Companies entering Germany need technical files that satisfy EU market access rules and large manufacturers' process questions.
• South Korea's branded-food groups operate on short convenience-food cycles that reward fast product testing and high-protein positioning. In July 2026, the national food-tech plan raised the target for research-support centers from seven to ten by 2030. Fungal protein sales in South Korea are forecast to expand at 8.9% CAGR by 2036, helped by public food-tech infrastructure despite local ingredient-recognition work. The main friction is translating platform-level policy support into ingredient specifications accepted by national branded-food manufacturers. Domestic partnerships offer the clearest entry route since local companies already manage regulatory work and channel testing.

Who are the notable companies in the Fungal Protein Market?

Angel Yeast Co., Ltd., The Protein Brewery, Enifer, Revyve, MycoTechnology, Inc., Lallemand Bio-Ingredients, Onego Bio, and The EVERY Company are the notable companies profiled in this market.

Competition separates direct fungal biomass and yeast protein producers from businesses that use fungi as a host for another functional protein. Direct producers control the clearest route to repeat ingredient revenue since their commercial output falls inside the defined market scope. Boundary precision-fermentation companies influence quality and scale expectations through industrial production benchmarks and competition for food-manufacturer protein budgets. Their programs also compete for budgets allocated to dairy protein ingredients and for fermentation capacity in adjacent food applications.

• Direct fungal and yeast protein positions include Angel Yeast Co., Ltd., The Protein Brewery, Enifer, and Revyve, with each showing current commercial protein production or scale-up.
• Fungal-fermentation ingredient positions include MycoTechnology, Inc. and Lallemand Bio-Ingredients through fungal-processing expertise or direct yeast-protein activity in food applications.
• Onego Bio and The EVERY Company are treated as boundary companies since their proteins are expressed through fungal fermentation hosts instead of fungal biomass ingredients.

Competitive Benchmarking: Fungal Protein Market

Company	Direct Fungal/Yeast Protein Exposure	Fermentation or Protein-Processing Scale	Food/Application Qualification Depth	Geographic Reach
Angel Yeast Co., Ltd.	High	High	High	Global
The Protein Brewery	High	Medium	High	USA, Europe, and Singapore
Enifer	High	Medium	High	Europe, USA, and Brazil
Revyve	High	Medium	High	Europe and North America
MycoTechnology, Inc.	Medium	Medium	High	USA, Great Britain, and Europe
Lallemand Bio-Ingredients	High	High	High	Global
Onego Bio	Low	Medium	High	USA and Europe
The EVERY Company	Low	High	High	North America and Europe

Scoring basis: High direct exposure requires current commercial evidence for fungal biomass or yeast protein sold as an ingredient. Medium identifies fungal processing or a close fermented-protein position, and Low marks a documented precision-fermentation protein at the market boundary. High scale requires industrial production or multi-site fermentation access, and Medium reflects one verified commercial plant or active scale-up. High qualification depth requires several food applications or regulator-reviewed use cases, whereas Medium identifies narrower evidence and Low identifies one verified application group. Geographic reach describes commercial coverage and does not contribute to the three capability scores used for benchmarking.

Key Developments in the Fungal Protein Market

• In November 2025, Angel Yeast Co., Ltd. started operating an 11,000-ton annual yeast protein line at Baiyang Biotechnology Park in Yichang for high-purity ingredient production.
• In June 2026, The Protein Brewery reported European Union authorization for Fermotein after positive voting by all 27 member states for its novel mycelium ingredient.
• In September 2025, Enifer secured self-affirmed GRAS status for PEKILO mycoprotein for USA food applications.

Key Players in the Fungal Protein Market

Direct Fungal and Yeast Protein Producers

• Angel Yeast Co., Ltd.
• The Protein Brewery
• Enifer
• Revyve

Fungal Fermentation and Ingredient Platforms

• MycoTechnology, Inc.
• Lallemand Bio-Ingredients

Boundary Precision-Fermentation Protein Platforms

• Onego Bio
• The EVERY Company

Fungal Protein Market - Report Scope

Coverage field	Report scope
Market breakdown	By source, end use application, and region.
Quantitative Units	USD Million.
Market Definition	Revenue from fungal protein ingredients sold within the stated source and end use application universe. Scope includes yeast-derived protein, Fusarium mycoprotein, brewer's yeast, baker's yeast, and mushroom-derived protein. Downstream finished-product revenue and unrelated substitute proteins are excluded.
Regions Covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa.
Countries Covered	USA, Japan, UK, Germany, South Korea, and more than twenty-five additional countries in the full report.
Key Companies Profiled	Angel Yeast Co., Ltd., The Protein Brewery, Enifer, Revyve, MycoTechnology, Inc., Lallemand Bio-Ingredients, Onego Bio, and The EVERY Company.
Forecast Period	2026 to 2036.
Approach	Market sizing reconciles supplier activity, end-use demand, product scope, country conditions, and forecast assumptions and excludes downstream finished-product revenue and unrelated substitute proteins.

Fungal Protein Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Fungal Protein Market by Segments

Fungal Protein Market segmented by Source:

• Yeast
  • Baker's Yeast
  • Fusarium venenatum
  • Brewer's Yeast
  • Mushroom

Fungal Protein Market segmented by End Use Application:

• Food & Beverage
  • Processed Food
• Animal Nutrition
• Dairy
• Pet Food
• Bakery
• Pharmaceuticals
• Aquaculture

Fungal Protein Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• Enifer. (2026, March 30). First commercial batch of PEKILO ready for pet food product development.
• Federal Food Safety and Veterinary Office. (2026, August 7). Authorisation of novel foods.
• USA Food and Drug Administration. (2025, September 23). GRAS Notice No. 1248: Yeast biomass produced by Kluyveromyces marxianus CCTCC M 20211265.
• USA Food and Drug Administration. (2025, November 18). GRAS Notice No. 1255: Mycelial biomass of Fusarium compactum CGMCC 41312 (fungal protein).
• The Protein Brewery. (2025, September 22). The Protein Brewery raises €30M in Series B equity to bring sustainable fungi-based proteins to market.
• USA Food and Drug Administration. (2026, March 3). GRAS Notice No. 1268: Mycelial biomass from Rhizomucor pusillus.
• Enifer. (2025, June 3). Enifer partners with FS to produce PEKILO Pet and PEKILO Aqua mycoproteins in Brazil from corn ethanol side streams.
• Onego Bio. (2025, September 22). Onego Bio receives FDA no questions letter on GRAS status of Bioalbumen.
• Food Standards Agency & Food Standards Scotland. (2026, January 6). Assessment of pea and rice protein fermented by Shiitake mycelia as novel food for use in food (RP1437).
• Statistisches Bundesamt (Destatis). (2026, July). Beschäftigte und Umsatz der Betriebe im Verarbeitenden Gewerbe: Deutschland, Jahre, Wirtschaftszweige (WZ2008 2-/3-/4-Steller).
• Ministry of Agriculture, Forestry and Fisheries, Japan. (2026, June 23).
• Ministry of Agriculture, Food and Rural Affairs, Republic of Korea. (2026, July 6). First basic plan for fostering the food-tech industry.
• Angel Yeast Co., Ltd. (2025, November 4). Angel Yeast starts operating new 11,000-ton yeast protein production line to meet global demand for sustainable nutrition.
• The Protein Brewery. (2026, June 17). EU authorizes Fermotein®.
• Enifer. (2025, September 10). Enifer secures self-affirmed GRAS status for PEKILO, paving way to FDA review.
• Revyve. (2025, September 23). Revyve secures €24 million funding to boost egg-replacing yeast proteins.
• Revyve. (2026, February 13). Quality by design: how we support food manufacturers with confidence.
• MycoTechnology, Inc. (2026, March 3). Honey Truffle Sweet Protein achieves regulatory milestone and enters USA market at commercial scale.
• Lallemand Bio-Ingredients. (2025, July 21). IFT First 2025 live: Lallemand Bio-Ingredients highlights its yeast protein offerings.
• The EVERY Company. (2026, June 15). EVERY and Huvepharma announce 4x production capacity expansion.
• Angel Yeast Co., Ltd. (2026, March 20). Quality protein no longer a luxury? Angel Yeast shows how at FIC 2026.
• ADM. (2026, July 14). ADM, EVERY Company partner to deliver USA-based commercial-scale production of OvoPro egg white protein.
• Onego Bio. (2025, March 12). Onego Bio chooses Jefferson County, Wisconsin for flagship egg protein manufacturing facility.
• The Protein Brewery. (2026, June 29). €18M Series B extension.
• The Protein Brewery. (2025, December 4). The Protein Brewery awarded half-million-euro grant to accelerate commercialization of next-generation Fermotein.
• The Protein Brewery. (2025, December 16). The Protein Brewery secures €2.3 million EU LIFE grant to bring next-gen nutritious mycoprotein powder to dairy alternatives.
• Enifer. (2026, March 24). Enifer moves PEKILO into FDA review.
• Enifer. (2026, May 12). Enifer and Rovio Pet Foods introduce dog treat made with PEKILO mycoprotein ingredient.
• Onego Bio. (2026, March 5). Onego Bio and Sigma Foods enter collaboration to strengthen egg protein innovation and supply resilience.
• Lallemand Inc. (2025, July 17). Lallemand acquires enzyme specialist Solyve.
• Quorn Foods. (2025, August 26). Quorn makes major change for ingredient-conscious fans.

This Report Answers

• How large is the fungal protein market in 2026 and 2036?
• Which operating conditions are increasing commercial fungal protein trials?
• Why does yeast account for 37.8% of source demand in 2026?
• Why does food & beverage account for 37.4% of end-use demand in 2026?
• How do the profiled country CAGRs compare through 2036?
• Which regulatory conditions can delay fungal protein qualification?
• Which companies have current commercial evidence in fungal and yeast protein?
• Where do fermentation scale and application support affect recurring orders?